Hawaii 2024 Regular Session

Hawaii House Bill HCR53 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	HOUSE OF REPRESENTATIVES H.C.R. NO. 53 THIRTY-SECOND LEGISLATURE, 2024 STATE OF HAWAII HOUSE CONCURRENT RESOLUTION REQUESTING THE AUDITOR TO assess the SOCIAL AND FINANCIAL effects of MANDATORY HEALTH INSURANCE COVERAGE FOR biomarker testing.
2	2
3	3	HOUSE OF REPRESENTATIVES H.C.R. NO. 53
4	4	THIRTY-SECOND LEGISLATURE, 2024
5	5	STATE OF HAWAII
6	6
7	7	HOUSE OF REPRESENTATIVES
8	8
9	9	H.C.R. NO.
10	10
11	11	53
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2024
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	HOUSE CONCURRENT
30	30
31	31	RESOLUTION
32	32
33	33
34	34
35	35
36	36
37	37	REQUESTING THE AUDITOR TO assess the SOCIAL AND FINANCIAL effects of MANDATORY HEALTH INSURANCE COVERAGE FOR biomarker testing.
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45	WHEREAS, biomarker testing is an invaluable tool in the diagnosis, treatment, appropriate managements, and ongoing monitoring of diseases or conditions; and WHEREAS, biomarker testing is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, a type of precision medicine that looks for genes, proteins, and other substances that can provide information about a patient's chronic condition; and WHEREAS, biomarker testing allows for a more precise and personalized approach to medical care by identifying specific genetic, molecular, or biochemical markers associated with an individual's disease; and WHEREAS, biomarker testing enables health care providers to tailor treatments based on the unique characteristics of a patient's condition, leading to more effective and targeted interventions; and WHEREAS, despite the fact that biomarker testing is essential to high-quality, personalized care to treat serious illness and enhance patients' quality of life, patients cannot easily access it; and WHEREAS, House Bill No. 2223, House Draft No. 1, Regular Session of 2024, require insurers, mutual benefit societies, and health maintenance organizations to provide coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; and WHEREAS, pursuant to section 23-51, Hawaii Revised Statutes, before any legislative measure that mandates health insurance coverage for specific health services, specific diseases, or certain providers of health care services as part of individual or group health insurance policies, can be considered, concurrent resolutions shall be passed that designate a specific legislative bill for the Auditor to review and prepare a report for submission to the Legislature that assesses both the social and financial effects of the proposed mandated coverage under that legislative bill; and WHEREAS, section 23-52, Hawaii Revised Statutes, further specifies the minimum information required for assessing the social and financial impact of the proposed health coverage mandate in the State Auditor's report; now, therefore, BE IT RESOLVED by the House of Representatives of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2024, the Senate concurring, that the Auditor is requested to assess, in accordance with sections 23‑51 and 23‑52, Hawaii Revised Statutes, the social and financial effects of mandating health insurance coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence, as provided in House Bill No. 2223, House Draft No. 1, Regular Session of 2024; and BE IT FURTHER RESOLVED that the Auditor is requested to submit a report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Auditor, Director of Commerce and Consumer Affairs, and Insurance Commissioner. OFFERED BY: _____________________________ Report Title: Auditor; Impact Assessment Report; Mandatory Health Insurance Coverage; Biomarker Testing
46	46
47	47	WHEREAS, biomarker testing is an invaluable tool in the diagnosis, treatment, appropriate managements, and ongoing monitoring of diseases or conditions; and
48	48
49	49
50	50
51	51	WHEREAS, biomarker testing is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, a type of precision medicine that looks for genes, proteins, and other substances that can provide information about a patient's chronic condition; and
52	52
53	53
54	54
55	55	WHEREAS, biomarker testing allows for a more precise and personalized approach to medical care by identifying specific genetic, molecular, or biochemical markers associated with an individual's disease; and
56	56
57	57
58	58
59	59	WHEREAS, biomarker testing enables health care providers to tailor treatments based on the unique characteristics of
60	60
61	61	a patient's condition, leading to more effective and targeted interventions; and
62	62
63	63
64	64
65	65	WHEREAS, despite the fact that biomarker testing is essential to high-quality, personalized care to treat serious illness and enhance patients' quality of life, patients cannot easily access it; and
66	66
67	67
68	68
69	69	WHEREAS, House Bill No. 2223, House Draft No. 1, Regular Session of 2024, require insurers, mutual benefit societies, and health maintenance organizations to provide coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; and
70	70
71	71
72	72
73	73	WHEREAS, pursuant to section 23-51, Hawaii Revised Statutes, before any legislative measure that mandates health insurance coverage for specific health services, specific diseases, or certain providers of health care services as part of individual or group health insurance policies, can be considered, concurrent resolutions shall be passed that designate a specific legislative bill for the Auditor to review and prepare a report for submission to the Legislature that assesses both the social and financial effects of the proposed mandated coverage under that legislative bill; and
74	74
75	75
76	76
77	77	WHEREAS, section 23-52, Hawaii Revised Statutes, further specifies the minimum information required for assessing the social and financial impact of the proposed health coverage mandate in the State Auditor's report; now, therefore,
78	78
79	79
80	80
81	81	BE IT RESOLVED by the House of Representatives of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2024, the Senate concurring, that the Auditor is requested to assess, in accordance with sections 23‑51 and 23‑52, Hawaii Revised Statutes, the social and financial effects of mandating health insurance coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence, as provided in House Bill No. 2223, House Draft No. 1, Regular Session of 2024; and
82	82
83	83
84	84
85	85	BE IT FURTHER RESOLVED that the Auditor is requested to submit a report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and
86	86
87	87
88	88
89	89	BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Auditor, Director of Commerce and Consumer Affairs, and Insurance Commissioner.
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97	OFFERED BY: _____________________________
98	98
99	99
100	100
101	101	OFFERED BY:
102	102
103	103	_____________________________
104	104
105	105
106	106
107	107
108	108
109	109	Report Title:
110	110
111	111	Auditor; Impact Assessment Report; Mandatory Health Insurance Coverage; Biomarker Testing